| American College of Clinical Pharmacy's vision of the future: postgraduate pharmacy residency training as a prerequisite for direct patient care practice JE Murphy, JM Nappi, JA Bosso, JJ Saseen, BA Hemstreet, MA Halloran, ... Pharmacotherapy 26 (5), 722-733, 2006 | 278 | 2006 |
| Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy A Prasad, RI Kuzniecky, RC Knowlton, TE Welty, RC Martin, M Mendez, ... Archives of neurology 60 (8), 1100-1105, 2003 | 133 | 2003 |
| Impact of vancomycin therapeutic drug monitoring on patient care TE Welty, AK Copa Annals of Pharmacotherapy 28 (12), 1335-1339, 1994 | 128 | 1994 |
| Vagus nerve stimulation for partial seizures. MD Privitera, TE Welty, DM Ficker, J Welge The Cochrane Database of Systematic Reviews, CD002896-CD002896, 2002 | 122* | 2002 |
| Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial MD Privitera, TE Welty, BE Gidal, FJ Diaz, R Krebill, JP Szaflarski, ... The Lancet Neurology 15 (4), 365-372, 2016 | 110 | 2016 |
| Treatment of refractory convulsive status epilepticus: a comprehensive review by the American Epilepsy Society Treatments Committee DG Vossler, JL Bainbridge, JG Boggs, EJ Novotny, T Loddenkemper, ... Epilepsy Currents 20 (5), 245-264, 2020 | 103 | 2020 |
| Cannabidiol: promise and pitfalls: Cannabidiol: promise and pitfalls TE Welty, A Luebke, BE Gidal Epilepsy currents 14 (5), 250-252, 2014 | 86 | 2014 |
| Management of hallucinations and psychosis in Parkinson's disease ML Eng, TE Welty The American journal of geriatric pharmacotherapy 8 (4), 316-330, 2010 | 78 | 2010 |
| Point-of-care testing: an introduction SL Gutierres, TE Welty Annals of Pharmacotherapy 38 (1), 119-125, 2004 | 77 | 2004 |
| Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies M Yamada, TE Welty Annals of Pharmacotherapy 45 (11), 1406-1415, 2011 | 75 | 2011 |
| Loss of seizure control associated with generic substitution of carbamazepine TE Welty, PR Pickering, BC Hale, R Arazi Annals of Pharmacotherapy 26 (6), 775-777, 1992 | 71 | 1992 |
| FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force JA French, E Perucca, JW Sander, L Bergfeldt, M Baulac, DS Auerbach, ... Epilepsy currents 21 (3), 150-153, 2021 | 62 | 2021 |
| The essential research curriculum for doctor of pharmacy degree programs MW Lee, PG Clay, WK Kennedy, MJ Kennedy, NM Sifontis, D Simonson, ... Pharmacotherapy 30 (9), 966, 2010 | 62 | 2010 |
| A controlled study of progabide in partial seizures: methodology and results IE Leppik, FE Dreifuss, R Porter, T Bowman, N Santilli, M Jacobs, ... Neurology 37 (6), 963-963, 1987 | 62 | 1987 |
| A double-blind crossover evaluation of progabide in partial seizures IE Leppik, FE Dreifuss, T Bowman-Cloyd, N Santilli, M Jacobs, C Crosby, ... Neurology 35 (4), 285, 1985 | 59 | 1985 |
| Bioequivalence between generic and branded lamotrigine in people with epilepsy: the EQUIGEN randomized clinical trial M Berg, TE Welty, BE Gidal, FJ Diaz, R Krebill, JP Szaflarski, ... Jama Neurology 74 (8), 919-926, 2017 | 55 | 2017 |
| Levetiracetam: a different approach to the pharmacotherapy of epilepsy TE Welty, BE Gidal, DM Ficker, MD Privitera Annals of Pharmacotherapy 36 (2), 296-304, 2002 | 54 | 2002 |
| Pathophysiology and treatment of subarachnoid hemorrhage. TE Welty, TG Horner Clinical pharmacy 9 (1), 35-39, 1990 | 52 | 1990 |
| Effect of limited transportation on medication adherence in patients with epilepsy TE Welty, SL Willis, EA Welty Journal of the American Pharmacists Association 50 (6), 698-703, 2010 | 39 | 2010 |
| Revisiting the significance of warfarin protein-binding displacement interactions CD Sands, ES Chan, TE Welty Annals of Pharmacotherapy 36 (10), 1642-1644, 2002 | 36 | 2002 |
